PRA Health Sciences Inc (PRAH) Shares Sold by ARP Americas LP

ARP Americas LP trimmed its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 28.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,200 shares of the medical research company’s stock after selling 1,300 shares during the quarter. ARP Americas LP’s holdings in PRA Health Sciences were worth $294,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Securian Asset Management Inc boosted its position in PRA Health Sciences by 1.4% during the fourth quarter. Securian Asset Management Inc now owns 7,171 shares of the medical research company’s stock worth $659,000 after purchasing an additional 100 shares in the last quarter. BB&T Securities LLC boosted its position in PRA Health Sciences by 3.5% during the fourth quarter. BB&T Securities LLC now owns 4,240 shares of the medical research company’s stock worth $389,000 after purchasing an additional 145 shares in the last quarter. D.A. Davidson & CO. boosted its position in PRA Health Sciences by 5.7% during the fourth quarter. D.A. Davidson & CO. now owns 2,698 shares of the medical research company’s stock worth $248,000 after purchasing an additional 146 shares in the last quarter. State of Alaska Department of Revenue lifted its position in shares of PRA Health Sciences by 2.1% in the fourth quarter. State of Alaska Department of Revenue now owns 7,134 shares of the medical research company’s stock valued at $656,000 after acquiring an additional 150 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC lifted its position in shares of PRA Health Sciences by 3.6% in the fourth quarter. Jaffetilchin Investment Partners LLC now owns 5,126 shares of the medical research company’s stock valued at $471,000 after acquiring an additional 177 shares in the last quarter. Institutional investors own 98.14% of the company’s stock.

Several analysts have recently issued reports on the company. BidaskClub downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 27th. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. SunTrust Banks upped their price objective on PRA Health Sciences to $120.00 and gave the company an “average” rating in a research report on Monday, March 4th. Finally, Robert W. Baird upped their price objective on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research report on Thursday, February 28th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $113.22.

PRA Health Sciences stock opened at $103.88 on Friday. The firm has a market capitalization of $6.78 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12. PRA Health Sciences Inc has a 52 week low of $79.20 and a 52 week high of $121.98. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 1.03.

COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://transcriptdaily.com/2019/03/15/pra-health-sciences-inc-prah-shares-sold-by-arp-americas-lp.html.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: How prevalent are 12b-1 fees?

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.